November 11, 2021 - … plasma-based biomarkers in the Phase 3 AHEAD 3-45 study of lecanemab (BAN2401), an investigational anti-amyloid beta … study will evaluate the efficacy of treatment with lecanemab in participants with preclinical AD and elevated … submission of a Biologics License Application (BLA) for lecanemab for the treatment of early AD, to the U.S. Food and …